Gw&K Investment Management Reduces $697K in Bio-Rad Laboratories, Inc. ($BIO)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Gw&K Investment Management trimmed its position in Bio-Rad Laboratories, Inc. ($BIO) by 1.34% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 174,708 shares of Bio-Rad Laboratories, Inc. after selling 2,375 shares during the quarter. Gw&K Investment Management's holdings in Bio-Rad Laboratories, Inc. were worth $51.30 million as of its most recent filing.
Bio-Rad Laboratories, Inc. Stock Down 24.3%
Shares of Bio-Rad Laboratories, Inc. ($BIO) traded around $293.61 on Saturday, down 24.3% for the day.
Bio-Rad Laboratories, Inc. Earnings
Analysts Set New Price Targets
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Get Bio-Rad Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.